(Q47644628)

English

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

scientific article published on 13 October 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

phase III clinical trial

0 references

zoledronic acid

1 reference

based on heuristic

inferred from title

object named as

Helen Marshall

8

0 references

object named as

Roger R Gomis

13

0 references

object named as

Federico Rojo

11

0 references

Andrew M. Hanby

4

object named as

Andrew Hanby

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

author name string

Robert Coleman

1

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Andrew Hall

2

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Joan Albanell

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Richard Bell

5

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

David Cameron

6

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

David Dodwell

7

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Joël Jean-Mairet

9

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Juan-Carlos Tercero

10

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Walter Gregory

12

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

publication date

13 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

18

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

11

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

1543-1552

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical course of bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Genes associated with breast cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone health in cancer patients: ESMO Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting metastasis-initiating cells through the fatty acid receptor CD36

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930603-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30603-4

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/29037984

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47644628&oldid=2163990574"